Business Insider
My Markets Watchlist
Markets Stocks

Bicara Therapeutics Inc Registered Shs Stock , BCAX

9.31 -0.11 -1.17%
03:59:59 PM EDT 6/20/2025 BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 06/20/2025 the closing price of the Bicara Therapeutics Inc Registered Shs share was $9.42 on BTT. Compared to the opening price on Friday 06/20/2025 on BTT of $9.69, this is a drop of 2.87%. Bicara Therapeutics Inc Registered Shs's market capitalization is $420.69 M by 54.54 M shares outstanding.

Bicara Therapeutics Stock Snapshot

9.05
Bid
150.00
Bid Size
9.40
Ask
900.00
Ask Size
6/20/2025
Date
3:59 PM
Time
18,593.00
Volume
9.42
Prev. Close
9.69
Open
514.28 M
Market Cap in USD
54.54 M
Number of Shares
54.54 M
Total Number of Shares
9.07
Day Low
9.69
Day High
9.31
0.00
Dividend in USD
0.00
Dividend Yield
60.08
Free Float in %
-4.05
EPS in USD
9.04
Book Value per Share in USD
-1.37
Cash Flow per Share in USD

Historical Prices for Bicara Therapeutics

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Bicara Therapeutics Analyst Data

Total Analysts: 8
Buy Ratings: 6 Neutral Ratings: 1 Sell Ratings: 1
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 8.00 Median: 27.63 Highest: 45.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Bicara Therapeutics Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
05/23/25 Wells Fargo & Co
Upgraded to Hold $8
05/16/25 H.C. Wainwright & Co.
Maintained Buy $41
04/17/25 Wells Fargo & Co
Maintained Sell $8
04/07/25 H.C. Wainwright & Co.
Maintained Buy $44
03/13/25 Cantor Fitzgerald
Maintained Buy $13.0100002288818
02/12/25 Wedbush Morgan Securities Inc.
Maintained Buy $31
02/06/25 Wedbush Morgan Securities Inc.
Maintained Buy $31
01/27/25 H.C. Wainwright & Co.
Maintained Buy $45

Bicara Therapeutics Estimates* in USD

  2025 2026 2027 2028 2029
Revenue - 0 0 36 126
Dividend - - - - -
Dividend Yield (in %) - - - - -
EPS -2.31 -2.65 -2.76 -3.22 -2.69
P/E Ratio -4.02 -3.52 -3.37 -2.89 -3.47
EBIT -151 -174 -203 -238 -226
EBITDA -166 -186 -207 - -
Net Profit -134 -160 -192 -227 -216
Net Profit Adjusted -130 -175 -219 -262 -212
Pre-Tax Profit -134 -160 -192 -227 -219
Pre-Tax Profit Reported - - - - -
EPS (Non-GAAP) ex. SOE -2.28 -2.59 -2.82 -2.98 -3.31
EPS (GAAP) -2.31 -2.65 -2.76 -3.22 -2.69
Gross Income - - - - 135
Cash Flow from Investing -1 -1 -1 -1 -1
Cash Flow from Operations -97 -105 -140 -188 -232
Cash Flow from Financing - - - - -
Cash Flow per Share - - - - -
Free Cash Flow - - - - -
Free Cash Flow per Share - - - - -
Book Value per Share 6.38 6.70 8.02 - -
Net Debt -272 -266 -374 -210 -244
Research & Development Exp. 114 131 153 162 185
Capital Expenditure - - - - -
Selling, General & Admin. Exp. 31 40 51 96 163
Shareholder’s Equity 344 - - - -
Total Assets - - - - -
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/26 		Next Year
ending 12/31/27
Earnings Estimates
No. of Analysts - 8 8 8 8
Average Estimate - -0.540 USD -0.561 USD -2.313 USD -2.646 USD
Year Ago - -0.313 USD -0.321 USD -1.249 USD -
Publish Date - - - - -
Revenue Estimates
No. of Analysts - 5 5 7 4
Average Estimate - 0 USD 0 USD 0 USD 0 USD
Year Ago - 0 USD 0 USD - -
Publish Date - - - - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022
Sales 0.00 0.00 0.00
Change of sales in % - - -
Gross profit on sales -0.06 -0.02 -0.01
Gross profit on sales change in % -194.74 -90.00 -
Operating income -82.39 -39.89 -37.66
Operating income change in % -106.55 -5.93 -
Income before tax -67.81 -51.98 -37.84
Income before tax change in % -30.45 -37.35 -
Income after tax -68.00 -51.99 -37.85
Income after tax change in % -30.80 -37.36 -

Balance Sheet in Mio. USD

2024 2023 2022
Total liabilities 77.32 15.47 23.98
Long-term liabilities per share 1.09 0.01 0.00
Equity 491.88 218.51 -17.28
Equity change in % - -50.57 -
Balance sheet total 569.20 233.98 6.70
Balance sheet total change in % 143.26 3,390.71 -

Key Data in USD

2024 2023 2022
Sales per share 0.00 0.00 0.00
P/E ratio (year end quote, basic EPS) - - -
P/E ratio (year end quote, diluted EPS) - - -
Dividend yield in % 0.00 - -
Equity ratio in % 86.42 93.39 -257.77
Debt ratio in % 13.58 6.61 357.77

Bicara Therapeutics Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Meisner Lara 06/15/2025 15,829.00 n/a 10.43 Sell No
Meisner Lara 06/15/2025 15,829.00 15,829.00 5.45 Buy No
Meisner Lara 03/13/2025 30,620.00 n/a 13.24 Sell No
Meisner Lara 03/13/2025 48,526.00 30,620.00 12.69 Sell No
Meisner Lara 03/13/2025 79,146.00 79,145.00 5.45 Buy No
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 09/16/2024 862,587.00 862,587.00 n/a Buy No
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 09/16/2024 35,000.00 897,587.00 18.00 Buy No
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 09/16/2024 862,587.00 862,587.00 n/a Buy No
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 09/16/2024 35,000.00 897,587.00 18.00 Buy No
FIL Ltd 09/15/2024 352,876.00 1,013,853.00 n/a Buy No
FIL Ltd 09/15/2024 606,885.00 660,977.00 n/a Buy No
FIL Ltd 09/15/2024 54,092.00 54,092.00 n/a Buy No
FMR LLC 09/15/2024 392,085.00 1,115,333.00 n/a Buy No
FMR LLC 09/15/2024 712,430.00 723,248.00 n/a Buy No
FMR LLC 09/15/2024 10,818.00 10,818.00 n/a Buy No
RA CAPITAL MANAGEMENT, L.P. 09/15/2024 152,480.00 2,652,575.00 18.00 Buy No
RA CAPITAL MANAGEMENT, L.P. 09/15/2024 1,680,520.00 4,303,418.00 18.00 Buy No
RA CAPITAL MANAGEMENT, L.P. 09/15/2024 2,500,095.00 2,500,095.00 n/a Buy No
RA CAPITAL MANAGEMENT, L.P. 09/15/2024 2,622,898.00 2,622,898.00 n/a Buy No
TPG Pace Beneficial II Sponsor, Series LLC 09/15/2024 1,960,425.00 1,960,425.00 n/a Buy No
Mazumdar-Shaw Kiran 09/15/2024 432,736.00 432,736.00 n/a Buy No
Mazumdar-Shaw Kiran 09/15/2024 324,552.00 324,552.00 n/a Buy No
Mazumdar-Shaw Kiran 09/15/2024 1,080,775.00 1,080,775.00 n/a Buy No
Mazumdar-Shaw Kiran 09/15/2024 4,327,365.00 4,443,122.00 n/a Buy No
Biocon Ltd 09/15/2024 1,080,775.00 1,080,775.00 n/a Buy No

Bicara Therapeutics Dividend Calendar

Date Name Dividend *yield Currency
2024 Bicara Therapeutics Inc Registered Shs 0.00 0.00 USD
2023 Bicara Therapeutics Inc Registered Shs - - USD
2022 Bicara Therapeutics Inc Registered Shs - - USD
*Yield of the Respective Date

Bicara Therapeutics Calendar

Event Estimate Info Date

Bicara Therapeutics Past Events

Event Actual EPS Info Date
Annual General Meeting -4.050 USD Annual General Meeting 06/09/2025
Earnings Report -0.680 USD Q1 2025 Earnings Release 05/13/2025
Earnings Report -0.390 USD Q4 2024 Earnings Release 03/27/2025
Earnings Report -1.600 USD Q3 2024 Earnings Release 11/12/2024

Bicara Therapeutics Profile

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.